메뉴 건너뛰기




Volumn 61, Issue 4, 2013, Pages 277-282

Branded versus generic clopidogrel in cardiovascular diseases: A systematic review

Author keywords

brand; cardiovascular; clopidogrel; generic; Plavix

Indexed keywords

CLOPIDOGREL; GENERIC DRUG;

EID: 84876412183     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827e5c60     Document Type: Review
Times cited : (21)

References (46)
  • 1
    • 0030590746 scopus 로고    scopus 로고
    • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    • CAPRIE Steering Committee
    • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339
    • (1996) Lancet , vol.348 , pp. 1329-1339
  • 2
    • 0037167686 scopus 로고    scopus 로고
    • Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
    • Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators
    • Budaj A, Yusuf S, Mehta SR, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626
    • (2002) Circulation , vol.106 , pp. 1622-1626
    • Budaj, A.1    Yusuf, S.2    Mehta, S.R.3
  • 3
    • 20144373281 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    • Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189
    • (2005) N Engl J Med , vol.352 , pp. 1179-1189
    • Sabatine, M.S.1    Cannon, C.P.2    Gibson, C.M.3
  • 5
    • 77958005516 scopus 로고    scopus 로고
    • Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial
    • CURRENT-OASIS 7 Trial Investigators
    • Mehta SR, Tanguay JF, Eikelboom JW, et al; CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010;376:1233-1243
    • (2010) Lancet , Issue.376 , pp. 1233-1243
    • Mehta, S.R.1    Tanguay, J.F.2    Eikelboom, J.W.3
  • 6
    • 34247869852 scopus 로고    scopus 로고
    • Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    • CHARISMA Investigators
    • Bhatt DL, Flather MD, Hacke W, et al CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1982-1988
    • Bhatt, D.L.1    Flather, M.D.2    Hacke, W.3
  • 7
    • 0037145863 scopus 로고    scopus 로고
    • Clopidogrel for the reduction of events during observation early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • CREDO Investigators
    • Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3
  • 8
    • 84455196353 scopus 로고    scopus 로고
    • Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers
    • Setiawati E, Yunaidi DA, Handayani LR, et al. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers. Arzneimittelforschung. 2011;61:681-684
    • (2011) Arzneimittelforschung , Issue.61 , pp. 681-684
    • Setiawati, E.1    Yunaidi, D.A.2    Handayani, L.R.3
  • 9
    • 77958187538 scopus 로고    scopus 로고
    • Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study
    • Shim CY, Park S, Song JW, et al. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. Clin Ther. 2010;32:1664-1673
    • (2010) Clin Ther , Issue.32 , pp. 1664-1673
    • Shim, C.Y.1    Park, S.2    Song, J.W.3
  • 10
    • 77952299363 scopus 로고    scopus 로고
    • Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study
    • Di Girolamo G, Czerniuk P, Bertuola R, et al. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32:161-170
    • (2010) Clin Ther , Issue.32 , pp. 161-170
    • Di Girolamo, G.1    Czerniuk, P.2    Bertuola, R.3
  • 11
    • 77952507198 scopus 로고    scopus 로고
    • Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: A clinical trial
    • Müller A, Octavio J, González MY, et al. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: A clinical trial. Am J Ther. 2010;17:351-356
    • (2010) Am J Ther , Issue.17 , pp. 351-356
    • Müller, A.1    Octavio, J.2    González, M.Y.3
  • 12
    • 71849117291 scopus 로고    scopus 로고
    • Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers
    • El Ahmady O, Ibrahim M, Hussein AM, et al. Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 2009;47:780-784
    • (2009) Int J Clin Pharmacol Ther , vol.47 , pp. 780-784
    • El Ahmady, O.1    Ibrahim, M.2    Hussein, A.M.3
  • 13
    • 65549122187 scopus 로고    scopus 로고
    • Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions
    • Filipe A, Almeida S, Franco Spínola AC, et al. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2009;47:187-194
    • (2009) Int J Clin Pharmacol Ther , vol.47 , pp. 187-194
    • Filipe, A.1    Almeida, S.2    Franco Spínola, A.C.3
  • 14
    • 77953691593 scopus 로고    scopus 로고
    • Clopidogrel and its salts: Any clinical implication?
    • Kummer O, Roffi M, Marti G, et al. Clopidogrel and its salts: Any clinical implication?. Rev Med Suisse. 2010;6:1127-1128
    • (2010) Rev Med Suisse , Issue.6 , pp. 1127-1128
    • Kummer, O.1    Roffi, M.2    Marti, G.3
  • 15
    • 25844468887 scopus 로고    scopus 로고
    • May 2009 plenary meeting monthly report Available at Accessed May 23
    • Committee for Medicinal Products for Human Use. May 2009 plenary meeting monthly report. Available at: Http://www.emea.europa.eu/docs/en-GB/ document-library/Committee-meeting-report/2009/10/WC500005831.pdf. Accessed May 23, 2012
    • (2012) Committee For Medicinal Products For Human Use
  • 16
    • 84876416087 scopus 로고    scopus 로고
    • Generic clopidogrel besilate makes inroads into European Plavix market
    • Available at
    • Generic clopidogrel besilate makes inroads into European Plavix market. Available at: Http://cardiobrief.org/2010/01/21/generic-clopidogrel- besilatemakes- inroads-into-european-plavix-market/#more-4375. Accessed May 23, 2012
    • Accessed May , vol.23 , pp. 2012
  • 18
    • 84876410953 scopus 로고    scopus 로고
    • In primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS
    • Available at
    • in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009. Available at: Http://www.dh.gov.uk/en/Consultations/ Liveconsultations/DH-110517. Accessed May 23, 2012
    • (2009) Accessed May , vol.23 , pp. 2012
  • 19
    • 33749054883 scopus 로고    scopus 로고
    • Delaying generic competition - corporate payoffs and the future of Plavix
    • Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N Engl J Med. 2006;355:1297-1300
    • (2006) N Engl J Med , vol.355 , pp. 1297-1300
    • Shuchman, M.1
  • 20
    • 84876419974 scopus 로고    scopus 로고
    • Bristol-Myers Squibb And Sanofi-aventis Announce U.S. Available at Accessed May 23
    • Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX-. Available at: Http://www.sanofi- aventis. ph/l/ph/en/download.jsp?file=D5F3060C-C299-4074-89FE-E4393B6D431F. pdf. Accessed May 23, 2012
    • (2012) FDA Decision To Grant Pediatric Exclusivity For PLAVIX
  • 21
    • 84876416558 scopus 로고    scopus 로고
    • IMS Health National Sales Perspectives Dec 2010 Available at Accessed May
    • IMS Health. The use of medicines in the United States: Review of 2010 National Sales Perspectives, Dec 2010. Available at: Http://www. imshealth.com/imshealth/Global/Content/IMS Institute/Documents/ IHII-UseOfMed-report.pdf. Accessed May 23, 2012
    • (2012) Use of Medicines In The United States: Review Of 2010 , vol.23
  • 23
    • 70049099036 scopus 로고    scopus 로고
    • Assessing risk of bias in included studies Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011)
    • In: Higgins JPT, Green S, eds chap 8. Available at
    • Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration. 2011:chap 8. Available at: Www.cochrane-handbook.org
    • (2011) Cochrane Collaboration
    • Higgins, J.P.T.1    Altman, D.G.2    Sterne, J.A.C.3
  • 25
    • 0037098201 scopus 로고    scopus 로고
    • Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes
    • Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575-1600
    • (2002) Stat Med , vol.21 , pp. 1575-1600
    • Deeks, J.J.1
  • 27
    • 0001910889 scopus 로고    scopus 로고
    • Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis
    • Egger M, Davey Smith G, Altman DG, eds 2nd ed. London, United Kingdom: BMJ Publication Group
    • Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, United Kingdom: BMJ Publication Group; 2001:313-335
    • (2001) Systematic Reviews in Health Care: Meta-Analysis in Context , pp. 313-335
    • Deeks, J.J.1    Altman, D.G.2    Bradburn, M.J.3
  • 28
    • 80051615049 scopus 로고    scopus 로고
    • Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial
    • Suh JW, Seung KB, Gwak CH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Clin Ther. 2011;33:1057-1068
    • (2011) Clin Ther , Issue.33 , pp. 1057-1068
    • Suh, J.W.1    Seung, K.B.2    Gwak, C.H.3
  • 29
    • 79958037331 scopus 로고    scopus 로고
    • The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study
    • Khosravi AR, Pourmoghadas M, Ostovan M, et al. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study. J Res Med Sci. 2011;16:640-650
    • (2011) J Res Med Sci , Issue.16 , pp. 640-650
    • Khosravi, A.R.1    Pourmoghadas, M.2    Ostovan, M.3
  • 30
    • 80054096419 scopus 로고    scopus 로고
    • Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting
    • Avdeeva LV, Shtegman OA, Mosina VA. Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting. Kardiologiia. 2011;51:23-26
    • (2011) Kardiologiia , Issue.51 , pp. 23-26
    • Avdeeva, L.V.1    Shtegman, O.A.2    Mosina, V.A.3
  • 31
    • 57549093120 scopus 로고    scopus 로고
    • Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis
    • Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008;300:2514-2526
    • (2008) JAMA , vol.300 , pp. 2514-2526
    • Kesselheim, A.S.1    Misono, A.S.2    Lee, J.L.3
  • 32
    • 80051826982 scopus 로고    scopus 로고
    • Quality of reporting of bioequivalence trials comparing generic to brand name drugs: A methodological systematic review
    • van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: A methodological systematic review. PLoS One. 2011;6:e23611
    • (2011) PLoS One , Issue.6
    • Van Der Meersch, A.1    Dechartres, A.2    Ravaud, P.3
  • 33
    • 84876416325 scopus 로고    scopus 로고
    • FDA guidance for industry - bioavailability and bioequivalence studies for orally administered drugs products - general considerations
    • Available at
    • FDA guidance for industry - bioavailability and bioequivalence studies for orally administered drugs products - general considerations. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070124.pdf. Accessed May 23, 2012
    • Accessed May , vol.23 , pp. 2012
  • 34
    • 84876416087 scopus 로고    scopus 로고
    • EMEA Committee for Medicinal Products for Human Use (CMPH). Guideline on the investigation of bioequivalence
    • Available at
    • EMEA Committee for Medicinal Products for Human Use (CMPH). Guideline on the investigation of bioequivalence. Available at: Http://www.ema. europa.eu/pdfs/human/qwp/140198enrev1fin.pdf. Accessed May 23, 2012
    • Accessed May , vol.23 , pp. 2012
  • 35
    • 77949936751 scopus 로고    scopus 로고
    • Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis
    • Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. Drugs. 2010;70:605-621
    • (2010) Drugs , Issue.70 , pp. 605-621
    • Kesselheim, A.S.1    Stedman, M.R.2    Bubrick, E.J.3
  • 36
    • 0038439242 scopus 로고    scopus 로고
    • Pharmaceutical industry sponsorship and research outcome and quality: Systematic review
    • Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ. 2003; 326:1167-1170
    • (2003) BMJ , vol.326 , pp. 1167-1170
    • Lexchin, J.1    Bero, L.A.2    Djulbegovic, B.3
  • 37
    • 33750036086 scopus 로고    scopus 로고
    • Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review
    • Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ. 2006;333:782
    • (2006) BMJ , vol.333 , pp. 782
    • Jørgensen, A.W.1    Hilden, J.2    Gøtzsche, P.C.3
  • 39
    • 33845331688 scopus 로고    scopus 로고
    • Patients' attitudes towards and experiences of generic drug substitution in Norway
    • Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28:284-289
    • (2006) Pharm World Sci , vol.28 , pp. 284-289
    • Kjoenniksen, I.1    Lindbaek, M.2    Granas, A.3
  • 40
    • 78751690811 scopus 로고    scopus 로고
    • Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland
    • Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20:185-191
    • (2011) Pharmacoepidemiol Drug Saf , Issue.20 , pp. 185-191
    • Heikkilä, R.1    Mäntyselkä, P.2    Ahonen, R.3
  • 41
    • 83455162856 scopus 로고    scopus 로고
    • Price, familiarity, and availability determine the choice of drug - A population-based survey five years after generic substitution was introduced in Finland
    • Heikkilä R, Mäntyselkä P, Ahonen R. Price, familiarity, and availability determine the choice of drug - a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol. 2011;11:20
    • (2011) BMC Clin Pharmacol , Issue.11 , pp. 20
    • Heikkilä, R.1    Mäntyselkä, P.2    Ahonen, R.3
  • 42
    • 32644435800 scopus 로고    scopus 로고
    • The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions
    • Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-337
    • (2006) Arch Intern Med , vol.166 , pp. 332-337
    • Shrank, W.H.1    Hoang, T.2    Ettner, S.L.3
  • 43
    • 77953431835 scopus 로고    scopus 로고
    • Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care
    • Ho PM, Tsai TT, Maddox TM, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care. Circ Cardiovasc Qual Outcomes. 2010;3:261-266
    • (2010) Circ Cardiovasc Qual Outcomes , Issue.3 , pp. 261-266
    • Ho, P.M.1    Tsai, T.T.2    Maddox, T.M.3
  • 44
    • 77956695087 scopus 로고    scopus 로고
    • Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization
    • Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis. 2010;103:363-375
    • (2010) Arch Cardiovasc Dis , Issue.103 , pp. 363-375
    • Tuppin, P.1    Neumann, A.2    Danchin, N.3
  • 45
    • 54949142220 scopus 로고    scopus 로고
    • Cardiovascular outcomes after a change in prescription policy for clopidogrel
    • Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359: 1802-1810
    • (2008) N Engl J Med , vol.359 , pp. 1802-1810
    • Jackevicius, C.A.1    Tu, J.V.2    Demers, V.3
  • 46
    • 32344435090 scopus 로고    scopus 로고
    • Generic substitution of antihypertensive drugs: Does it affect adherence?
    • Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: Does it affect adherence? Ann Pharmacother. 2006;40:15-20
    • (2006) Ann Pharmacother , vol.40 , pp. 15-20
    • Van Wijk, B.L.1    Klungel, O.H.2    Heerdink, E.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.